Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

micropillar thumbnail
New Findings | 6 Jul 2014

Novel Remyelination Assay Allows High-Throughput Drug Screening

A new technology uses the actual myelin-making behavior of cells to look for drugs that may promote remyelination and prevent disability-causing nerve damage in people with MS. The first candidate is in clinical trials.

Carol Cruzan Morton
In the brains and spinal cords of people with multiple sclerosis, the repair of demyelinating lesions remains...
Clinical Research, Drug Development, Laboratory Research
fatigue mirror
New Findings | 2 Jul 2014

Damage to Strategic Brain Regions May Explain Fatigue in MS

Atrophy in the right anterior thalamic radiation, the right inferior temporal gyrus, and several other specific brain regions is linked to fatigue in persons with multiple sclerosis

Laurie Barclay, M.D.
Microstructural abnormalities and atrophy of white and gray matter in strategic brain regions are linked to...
Clinical Research
Peginterferon beta 1a
New Findings | 2 Jul 2014

A Better Interferon?

Subcutaneous injections of pegylated interferon β-1a once every 2 weeks may improve recovery from relapses and increase the likelihood of freedom from measurable disease activity

Lisa J. Bain
Pegylated interferon β-1a continues to show benefits similar to other currently available...
Clinical Research, Drug Development, Meetings
MACPF
New Findings | 24 Jun 2014

A Complementary Approach to Treating MS?

A new study bolsters the theory that the complement system drives persistent axon damage during remission. Anticomplement therapies may help.

Jennie Dusheck, M.A.
Mounting evidence suggests that the immune system’s ancient complement system plays a role in...
Drug Development, Laboratory Research
GM-CSF illustration
New Findings | 23 Jun 2014

GM-CSF: A Target for Brain Inflammation Intervention in MS?

Inhibiting granulocyte-macrophage colony-stimulating factor might be a new therapeutic route to treat MS, and a novel T cell subtype may lead the way

Ricki Lewis, Ph.D.
Inhibiting the activity of a cytokine well known for boosting white blood cell counts following...
Clinical Research, Laboratory Research
Olfactory system
New Findings | 10 Jun 2014

Sniffing Out Demyelination

Researchers have found evidence of demyelination and axonal loss in olfactory tissue. Could the olfactory system be an important link between environmental exposures and MS?

Carol Cruzan Morton
Whether it’s an aromatic meal, fragrant flowers, or a gas leak—some people with multiple sclerosis have...
Clinical Research
MS phenotypes
New Findings | 10 Jun 2014

New MS Clinical Course Descriptions Reflect Disease Activity

Refined descriptors for the course of MS, replacing those in use since 1996, are intended to make communication with patients clearer and to enhance the design and conduct of clinical trials

Laurie Barclay, M.D.
The International Advisory Committee on Clinical Trials in Multiple Sclerosis has issued refined descriptors for MS course that include...
Clinical Research
OCT retina
New Findings | 10 Jun 2014

Optical Coherence Tomography: New Evidence Lends Support for MS Diagnosis

By measuring retinal thinning, optical coherence tomography (OCT) provides an inexpensive and noninvasive means of assessing CNS pathology in people with MS. Two new studies show that OCT findings correlate with spinal cord and cortical MRI measures.

Lisa J. Bain
Over the past 30 years, magnetic resonance imaging has emerged as a primary tool for...
Clinical Research
New Findings | 3 Jun 2014

PPMS vs. RRMS: A Distinction Without a Difference?

A study using ultrahigh-field MRI found identical brain lesions in primary progressive and relapsing-remitting multiple sclerosis

Mitch Leslie
The relationship between primary progressive multiple sclerosis and relapsing-remitting multiple sclerosis continues to...
Clinical Research

Pages